KURA News and Press, Kura Oncology Inc. From 02/19/20

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is...

SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financial results ...

Last month I was using our IOMachine methodology to research Kura Oncology ( KURA ) in order to see if I can recommend it to TPT subscribers as a proper investible stock. The method consists of a number of semi-automated parameters I check for against the company data, and see how the company ...

Kura Oncology (NASDAQ: KURA ) Head of Development and Chief Medical Officer Antonio Gualberto, M.D., Ph.D., will step down effective February 7 to pursue other opportunities. More news on: Kura Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...

– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran Dr. Bridget Martell named acting Chief Medical Officer – &#...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference. ...

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms. Flow...

– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first quarter of 2021 – SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE)...

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients with KIR mutations, a CXCL pathway-associated biomarker – &#...